BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 33822841)

  • 1. Uncovering the dosage-dependent roles of Arid1a in gastric tumorigenesis for combinatorial drug therapy.
    Loe AKH; Francis R; Seo J; Du L; Wang Y; Kim JE; Hakim SW; Kim JE; He HH; Guo H; Kim TH
    J Exp Med; 2021 Jun; 218(6):. PubMed ID: 33822841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ARID1A deficiency in EBV-positive gastric cancer is partially regulated by EBV-encoded miRNAs, but not by DNA promotor hypermethylation.
    Kase K; Saito M; Nakajima S; Takayanagi D; Saito K; Yamada L; Ashizawa M; Nakano H; Hanayama H; Onozawa H; Okayama H; Endo H; Fujita S; Sakamoto W; Saze Z; Momma T; Mimura K; Ohki S; Shiraishi K; Kohno T; Kono K
    Carcinogenesis; 2021 Feb; 42(1):21-30. PubMed ID: 33196828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis.
    Reske JJ; Wilson MR; Holladay J; Siwicki RA; Skalski H; Harkins S; Adams M; Risinger JI; Hostetter G; Lin K; Chandler RL
    PLoS Genet; 2021 Dec; 17(12):e1009986. PubMed ID: 34941867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromatin remodeling gene AT-rich interactive domain-containing protein 1A suppresses gastric cancer cell proliferation by targeting PIK3CA and PDK1.
    Zhang Q; Yan HB; Wang J; Cui SJ; Wang XQ; Jiang YH; Feng L; Yang PY; Liu F
    Oncotarget; 2016 Jul; 7(29):46127-46141. PubMed ID: 27323812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implication of ARID1A Undercurrents and PDL1, TP53 Overexpression in Advanced Gastric Cancer.
    Qadir J; Majid S; Khan MS; Rashid F; Wani MD; Bhat SA
    Pathol Oncol Res; 2021; 27():1609826. PubMed ID: 34924820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virus-host interactions in carcinogenesis of Epstein-Barr virus-associated gastric carcinoma: Potential roles of lost ARID1A expression in its early stage.
    Abe H; Kunita A; Otake Y; Kanda T; Kaneda A; Ushiku T; Fukayama M
    PLoS One; 2021; 16(9):e0256440. PubMed ID: 34469459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic role of ARID1A negative expression in gastric cancer.
    Ashizawa M; Saito M; Min AKT; Ujiie D; Saito K; Sato T; Kikuchi T; Okayama H; Fujita S; Endo H; Sakamoto W; Momma T; Ohki S; Goto A; Kono K
    Sci Rep; 2019 May; 9(1):6769. PubMed ID: 31043675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ARID1A-mutated ovarian cancers depend on HDAC6 activity.
    Bitler BG; Wu S; Park PH; Hai Y; Aird KM; Wang Y; Zhai Y; Kossenkov AV; Vara-Ailor A; Rauscher FJ; Zou W; Speicher DW; Huntsman DG; Conejo-Garcia JR; Cho KR; Christianson DW; Zhang R
    Nat Cell Biol; 2017 Aug; 19(8):962-973. PubMed ID: 28737768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability.
    Abe H; Maeda D; Hino R; Otake Y; Isogai M; Ushiku AS; Matsusaka K; Kunita A; Ushiku T; Uozaki H; Tateishi Y; Hishima T; Iwasaki Y; Ishikawa S; Fukayama M
    Virchows Arch; 2012 Oct; 461(4):367-77. PubMed ID: 22915242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ARID1A facilitates KRAS signaling-regulated enhancer activity in an AP1-dependent manner in colorectal cancer cells.
    Sen M; Wang X; Hamdan FH; Rapp J; Eggert J; Kosinsky RL; Wegwitz F; Kutschat AP; Younesi FS; Gaedcke J; Grade M; Hessmann E; Papantonis A; Strӧbel P; Johnsen SA
    Clin Epigenetics; 2019 Jun; 11(1):92. PubMed ID: 31217031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DDIT4 promotes gastric cancer proliferation and tumorigenesis through the p53 and MAPK pathways.
    Du F; Sun L; Chu Y; Li T; Lei C; Wang X; Jiang M; Min Y; Lu Y; Zhao X; Nie Y; Fan D
    Cancer Commun (Lond); 2018 Jul; 38(1):45. PubMed ID: 29976242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer.
    Wang DD; Chen YB; Pan K; Wang W; Chen SP; Chen JG; Zhao JJ; Lv L; Pan QZ; Li YQ; Wang QJ; Huang LX; Ke ML; He J; Xia JC
    PLoS One; 2012; 7(7):e40364. PubMed ID: 22808142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer.
    Yamada L; Saito M; Thar Min AK; Saito K; Ashizawa M; Kase K; Nakajima S; Onozawa H; Okayama H; Endo H; Fujita S; Sakamoto W; Saze Z; Momma T; Mimura K; Ohki S; Kono K
    Gastric Cancer; 2021 Jan; 24(1):60-71. PubMed ID: 32506298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A CRISPR/Cas9-Engineered
    Lo YH; Kolahi KS; Du Y; Chang CY; Krokhotin A; Nair A; Sobba WD; Karlsson K; Jones SJ; Longacre TA; Mah AT; Tercan B; Sockell A; Xu H; Seoane JA; Chen J; Shmulevich I; Weissman JS; Curtis C; Califano A; Fu H; Crabtree GR; Kuo CJ
    Cancer Discov; 2021 Jun; 11(6):1562-1581. PubMed ID: 33451982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ZFPM2-AS1, a novel lncRNA, attenuates the p53 pathway and promotes gastric carcinogenesis by stabilizing MIF.
    Kong F; Deng X; Kong X; Du Y; Li L; Zhu H; Wang Y; Xie D; Guha S; Li Z; Guan M; Xie K
    Oncogene; 2018 Nov; 37(45):5982-5996. PubMed ID: 29985481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive molecular phenotyping of
    Xu C; Huang KK; Law JH; Chua JS; Sheng T; Flores NM; Pizzi MP; Okabe A; Tan ALK; Zhu F; Kumar V; Lu X; Benitez AM; Lian BSX; Ma H; Ho SWT; Ramnarayanan K; Anene-Nzelu CG; Razavi-Mohseni M; Abdul Ghani SAB; Tay ST; Ong X; Lee MH; Guo YA; Ashktorab H; Smoot D; Li S; Skanderup AJ; Beer MA; Foo RSY; Wong JSH; Sanghvi K; Yong WP; Sundar R; Kaneda A; Prabhakar S; Mazur PK; Ajani JA; Yeoh KG; So JB; Tan P;
    Gut; 2023 Sep; 72(9):1651-1663. PubMed ID: 36918265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAB zinc-finger protein 382 regulates epithelial-mesenchymal transition and functions as a tumor suppressor, but is silenced by CpG methylation in gastric cancer.
    Pei L; He X; Li S; Sun R; Xiang Q; Ren G; Xiang T
    Int J Oncol; 2018 Sep; 53(3):961-972. PubMed ID: 29956735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of ARID1A Expression is Related to Gastric Cancer Progression, Epstein-Barr Virus Infection, and Mismatch Repair Deficiency.
    Han N; Kim MA; Lee HS; Kim WH
    Appl Immunohistochem Mol Morphol; 2016; 24(5):320-5. PubMed ID: 26067140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging roles of ARID1A in tumor suppression.
    Wu RC; Wang TL; Shih IeM
    Cancer Biol Ther; 2014 Jun; 15(6):655-64. PubMed ID: 24618703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unique characteristics of
    Kim YS; Jeong H; Choi JW; Oh HE; Lee JH
    Saudi J Gastroenterol; 2017; 23(5):268-274. PubMed ID: 28937020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.